Hormone Therapy: What the Evidence Actually Shows

In November 2025, FDA/HHS announced major changes to menopausal hormone-therapy labeling. On February 12, 2026, FDA approved removal of boxed-warning language related to cardiovascular disease, breast cancer, and probable dementia from several menopausal hormone therapy products. The endometrial-cancer boxed warning remains for systemic estrogen-alone products. This did not mean hormone therapy suddenly became risk-free; it meant the old blanket-warning framework no longer accurately reflected the accumulated evidence, including differences in age, timing, formulation, route, and the specific hormones used. [1–3]

Read the FDA February 2026 announcement

That does not mean hormone therapy has no risks. It means the risks are more individualized than the old blanket warning suggested. If you have been told "hormones are dangerous," the honest next step is an individualized conversation about your age, timing, formulation, route and risk profile — which is exactly what our Hormone Optimization evaluation is built around.

Perimenopause and menopause change hormone signaling throughout the body. Estradiol falls, ovulation becomes irregular and progesterone production changes, and androgen physiology changes with age and ovarian function. Hormone receptors are present in far more than reproductive organs: bone, muscle, brain, skin, bladder, urethra, vagina, blood vessels and other tissues all respond to sex-hormone signaling.

That is why symptoms that look unrelated can arrive together: hot flashes, poor sleep, vaginal dryness, bladder irritability, recurrent UTI symptoms, loss of libido or orgasmic response, skin thinning, muscle loss, changing fat distribution and accelerated bone loss. Treating each downstream problem separately can miss the endocrine transition that connects many of them.

This is the same framework behind our Menopause & Perimenopause care path — symptoms are evaluated as one endocrine transition, not as unrelated complaints.

• Estradiol — important for vasomotor regulation, vaginal/urinary tissues, bone and other estrogen-responsive systems.
• Progesterone — important for endometrial protection when systemic estrogen is used in a woman with a uterus, with additional sleep/neurosteroid effects.
• Testosterone — a normal and important female hormone involved in libido, arousal, orgasmic function, muscle, bone and androgen signaling. Women require much lower levels than men, but lower does not mean unimportant.

Why testosterone matters in women

Women naturally produce testosterone throughout life, and research supports an important role for testosterone in female sexual function — including desire, arousal, pleasure and orgasmic response. It is also involved in androgen signaling in muscle, bone and other tissues. Lower levels than men do not make it unimportant: testosterone is part of normal female hormone health, and it deserves the same evidence-based conversation as estrogen and progesterone. Learn more on our Testosterone Therapy page.

SSRIs and SNRIs can reduce hot flashes and are useful options for some women, especially when systemic estrogen is contraindicated or unwanted. But they are not hormone replacement — the side-by-side evidence:

Bone is living tissue that is constantly being broken down and rebuilt. Estrogen restrains bone resorption; when estrogen falls around menopause, bone turnover shifts toward net loss. Nutrition and mechanical loading matter too: adequate protein, calcium, vitamin D, vitamin K status, magnesium and resistance/impact exercise all contribute to skeletal health. Men also lose bone as sex-hormone signaling changes with age.

Antiresorptive drugs such as alendronate (Fosamax) can reduce common osteoporotic fractures in appropriately selected patients, but they work by suppressing bone resorption and therefore bone turnover. Their prescribing information also warns about rare osteonecrosis of the jaw and atypical low-trauma femoral fractures, with risk rising in some patients with longer exposure. That is why osteoporosis treatment should not stop at "take a bone drug" — the causes of bone loss, nutritional status, hormone status, loading, fall risk and medication tradeoffs all matter. [11]

Oral estrogen undergoes first-pass liver metabolism and increases hepatic production of clotting factors. Transdermal estradiol bypasses that first-pass effect. Observational studies and meta-analyses consistently report higher venous-thromboembolism risk with oral estrogen, whereas transdermal estradiol has shown little or no measurable increase in VTE risk in most studies. [12,13]

Smoking changes risk assessment — it does not automatically mean "never estrogen." The route and formulation matter. Oral estrogen undergoes first-pass hepatic metabolism and has a more prothrombotic effect, whereas transdermal estradiol bypasses first-pass liver exposure and has shown little or no increase in prothrombotic markers and VTE risk in observational studies. ACOG specifically advises considering the thrombosis-sparing properties of transdermal estrogen. Combined hormonal contraceptives containing ethinyl estradiol are a different exposure: CDC classifies combined hormonal contraception as category 3 for smokers age 35 or older who smoke fewer than 15 cigarettes/day and category 4 at 15 or more cigarettes/day. The clinically useful question is therefore not simply "Do you smoke?" but "What estrogen, what route, what dose, what age, and what individual risk factors?" [12,13,17,18]

Sex hormones act through receptors distributed throughout the body, and research continues to uncover endocrine signaling in tissues and diseases that were historically studied as if they were unrelated to hormones. This includes active research into hormone-receptor signaling in skin, brain, immune biology and cancers such as melanoma. These are emerging areas, not established treatment claims — but they are a reminder that our understanding of hormone biology is still incomplete.